JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB278104

Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Insulin Receptor beta antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human, Mouse, Recombinant full length protein - Mouse, Rat samples.

View Alternative Names

CD220, Insulin receptor, IR

10 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Immunohistochemical analysis of paraffin-embedded human liver tissue labeling Insulin Receptor beta with ab278100 at 1/2000 (0.24 μg/ml) followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on human liver. The section was incubated with ab278100 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Immunohistochemical analysis of paraffin-embedded human kidney cancer tissue labeling Insulin Receptor beta with ab278100 at 1/2000 (0.24 μg/ml) followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Mainly positive staining on endothelial cells of human kidney cancer (PMID : 20182859). The section was incubated with ab278100 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Immunohistochemical analysis of paraffin-embedded rat liver tissue labeling Insulin Receptor beta with ab278100 at 1/2000 (0.24 μg/ml) followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on rat liver. The section was incubated with ab278100 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Immunohistochemical analysis of paraffin-embedded mouse liver tissue labeling Insulin Receptor beta with ab278100 at 1/2000 (0.24 μg/ml) followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on mouse liver. The section was incubated with ab278100 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • WB

Lab

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Bands of 95KDa and 45KDa respectively represent full length and the proteolytic cleavage fragment (β') of insulin receptor beta subunit.

The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 19017805, 20655470, 2859121, 1617668, 29099049).

Low expression : T-47D (PMID : 1617668, 29099049)

Exposure time : 3 minutes

All lanes:

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] (<a href='/en-us/products/primary-antibodies/insulin-receptor-beta-antibody-epr23566-103-ab278100'>ab278100</a>) at 1/1000 dilution

Lane 1:

T47D (human ductal breast epithelial tumor epithelial cell), whole cell lysate at 20 µg

Lane 2:

MDA-MB-231 (human breast adenocarcinoma epithelial cell), whole cell lysate at 20 µg

Lane 3:

PC-3 (human prostate adenocarcinoma epithelial cell), whole cell lysate at 20 µg

Lane 4:

HepG2 (human hepatocellar carcinoma epithelial cell), whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 210 kDa,45 kDa,95 kDa

false

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • WB

Lab

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Bands of 95KDa and 45KDa respectively represent full length and the proteolytic cleavage fragment (β') of insulin receptor beta subunit.

The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 19017805, 20655470, 2859121, 1617668, 29099049).

Exposure time : 3 minutes

All lanes:

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] (<a href='/en-us/products/primary-antibodies/insulin-receptor-beta-antibody-epr23566-103-ab278100'>ab278100</a>) at 1/1000 dilution

Lane 1:

Human liver tissue lysate at 20 µg

Lane 2:

Human kidney tissue lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 45 kDa,95 kDa

false

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • WB

Lab

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Bands of 95KDa and 45KDa respectively represent full length and the proteolytic cleavage fragment (β') of insulin receptor beta subunit.

The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 19017805, 20655470, 2859121, 1617668, 29099049).

This blot was developed using a higher sensitivity ECL substrate.

Exposure time : 3 minutes

All lanes:

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] (<a href='/en-us/products/primary-antibodies/insulin-receptor-beta-antibody-epr23566-103-ab278100'>ab278100</a>) at 1/1000 dilution

Lane 1:

LNCaP (human prostate carcinoma epithelial cell), whole cell lysate at 20 µg

Lane 2:

LNCaP (human prostate carcinoma epithelial cell) treated with PNGase F whole cell lysate at 20 µg

Lane 3:

C2C12 (mouse myoblasts myoblast), whole cell lysate at 20 µg

Lane 4:

C2C12 (mouse myoblasts myoblast) treated with PNGase F whole cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 210 kDa,45 kDa,95 kDa

false

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • WB

Lab

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Bands of 95KDa and 45KDa respectively represent full length and the proteolytic cleavage fragment (β') of insulin receptor beta subunit.

The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 19017805, 20655470, 2859121, 1617668, 29099049).

This blot was developed using a higher sensitivity ECL substrate.

Exposure time : 3 minutes

All lanes:

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] (<a href='/en-us/products/primary-antibodies/insulin-receptor-beta-antibody-epr23566-103-ab278100'>ab278100</a>) at 1/1000 dilution

Lane 1:

Mouse liver tissue lysate at 20 µg

Lane 2:

Mouse skeletal muscle tissue lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 210 kDa,45 kDa,95 kDa

false

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • WB

Lab

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Bands of 95KDa and 45KDa respectively represent full length and the proteolytic cleavage fragment (β') of insulin receptor beta subunit.

The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 19017805, 20655470, 2859121, 1617668, 29099049).

This blot was developed using a higher sensitivity ECL substrate.

Exposure time : 3 minutes

All lanes:

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] (<a href='/en-us/products/primary-antibodies/insulin-receptor-beta-antibody-epr23566-103-ab278100'>ab278100</a>) at 1/1000 dilution

Lane 1:

Rat liver tissue lysate at 20 µg

Lane 2:

AR42J (rat pancreatic tumor epithelial cell), whole cell lysate at 20 µg

Lane 3:

Rat-1 (rat embryonic fibroblast), whole cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 210 kDa,45 kDa,95 kDa

false

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)
  • WB

Lab

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] - BSA and Azide free (AB278104)

This data was developed using ab278100, the same antibody clone in a different buffer formulation.

Blocking and diluting buffer and concentration : 5% NFDM/TBST

This blot was developed using a higher sensitivity ECL substrate.

Exposure time : 3 minutes

All lanes:

Western blot - Anti-Insulin Receptor beta antibody [EPR23566-103] (<a href='/en-us/products/primary-antibodies/insulin-receptor-beta-antibody-epr23566-103-ab278100'>ab278100</a>) at 1/1000 dilution

All lanes:

Recombinant mouse INSR active protein (aa 28-748 & aa 753-946), 20 ng

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 150 kDa,82 kDa

false

  • Unconjugated

    Anti-Insulin Receptor beta antibody [EPR23566-103]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR23566-103

Isotype

IgG

Carrier free

Yes

Reacts with

Mouse, Rat, Human

Applications

WB, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Complementary Products

Assay Kits

AB65336

Triglyceride Assay Kit - Quantification

Biochemical assay - Triglyceride Assay Kit - Quantification (AB65336)

  • 4
  • 4
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB181547

Anti-Insulin antibody [EPR17359]

BOND RX™ Validated|RabMAb|Recombinant|Lab Essentials|20ul selling size|Advanced Validation

Multiplex immunohistochemistry - Anti-Insulin antibody [EPR17359] (AB181547)

  • 5
  • 11
Primary Antibodies

AB9485

Anti-GAPDH antibody - Loading Control

BOND RX™ Validated|Lab Essentials

Immunocytochemistry/ Immunofluorescence - Anti-GAPDH antibody - Loading Control (AB9485)

  • 5
  • 88
Primary Antibodies

AB33780

Anti-Glucose Transporter GLUT4 antibody

BOND RX™ Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Glucose Transporter GLUT4 antibody (AB33780)

  • 4
  • 12
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Mouse": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Rat": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Recombinant full length protein - Mouse": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }
style
left-column

Product details

ab278104 is the carrier-free version of ab278100.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Insulin Receptor beta (IR beta) also known as IRB is a subunit of the insulin receptor which is a transmembrane protein deeply involved in cellular signal transduction. This receptor has two main subunits: alpha and beta. The insulin receptor beta is responsible for the transduction of insulin's metabolic and mitogenic signals through its intrinsic tyrosine kinase activity. This subunit has a molecular mass of approximately 95 kDa and is predominantly expressed on the surface of insulin-responsive cells like liver muscle and adipose tissue cells where it mediates glucose uptake and metabolism. Its expression is usually determined through methods such as insulin western blot.
Biological function summary

The function of insulin receptor beta involves both glucose homeostasis and growth regulation as part of the tetrameric insulin receptor complex. Upon insulin binding to the receptor IR beta undergoes autophosphorylation leading to the recruitment and phosphorylation of various intracellular substrates. This interaction plays a critical role in mediating the effects of insulin such as promoting glucose uptake in cells and modulating lipid metabolism. This receptor subunit is also referred to in studies as insulin 44 or insulin 37 referring to different conceptual sizes or regulatory stages.

Pathways

The insulin signaling pathway represents the main route facilitated by insulin receptor beta. This pathway is essential for regulating glucose transport lipid metabolism and protein synthesis. Perturbations in this cascade are commonly associated with insulin resistance. The insulin receptor beta interacts with other proteins like insulin receptor substrates (IRS) during this pathway which subsequently activate key downstream pathways such as the PI3K-AKT pathway critical for cell survival and growth. This protein also plays a role in MAP kinase signaling through which it impacts gene expression related to cell growth.

Insulin receptor beta relates prominently to type 2 diabetes mellitus and metabolic syndrome. Mutations or dysfunctions in IR beta can lead to defective insulin signaling causing insulin resistance a major hallmark of these conditions. Additionally it is implicated in polycystic ovary syndrome (PCOS) where altered insulin signaling influences the endocrine and metabolic profiles. Proteins like insulin receptor substrates are often examined in these contexts as they directly interact with IR beta and modulate the downstream effects seen in these diseases.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways : the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for : anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed : 12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed : 16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. In adipocytes, inhibits lipolysis (By similarity).
See full target information INSR
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com